Literature DB >> 17456516

Target practice: oncology drug development in the era of genomic medicine.

Richard L Schilsky1.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17456516     DOI： 10.1177/1740774507076807

Source DB:  PubMed          Journal:  Clin Trials        ISSN： 1740-7745            Impact factor:   2.486


× No keyword cloud information.
  5 in total

Review 1.  Recent progress and clinical importance on pharmacogenetics in cancer therapy.

Authors:  Thomas I Peng Soh; Wei Peng Yong; Federico Innocenti
Journal:  Clin Chem Lab Med       Date:  2011-09-28       Impact factor: 3.694

Review 2.  Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?

Authors:  Lothar R Pilz; Christian Manegold; Gerald Schmid-Bindert
Journal:  Transl Lung Cancer Res       Date:  2012-03

3.  Adaptive enrichment designs for clinical trials.

Authors:  Noah Simon; Richard Simon
Journal:  Biostatistics       Date:  2013-03-21       Impact factor: 5.899

4.  Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.

Authors:  Stefan Michiels; Richard F Potthoff; Stephen L George
Journal:  Stat Med       Date:  2011-02-23       Impact factor: 2.373

5.  Clinical trials in the era of personalized oncology.

Authors:  Michael L Maitland; Richard L Schilsky
Journal:  CA Cancer J Clin       Date:  2011-10-27       Impact factor: 508.702
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.